Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research
For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2008-04, Vol.41 (7), p.635-642 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 642 |
|---|---|
| container_issue | 7 |
| container_start_page | 635 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 41 |
| creator | Bishop, M R Logan, B R Gandham, S Bolwell, B J Cahn, J-Y Lazarus, H M Litzow, M R Marks, D I Wiernik, P H McCarthy, P L Russell, J A Miller, C B Sierra, J Milone, G Keating, A Loberiza, F R Giralt, S Horowitz, M M Weisdorf, D J |
| description | For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12–170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients. |
| doi_str_mv | 10.1038/sj.bmt.1705952 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2587442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A186436837</galeid><sourcerecordid>A186436837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c611t-eb3e2dbcdc6d3d6034fafdf5507bda743f83b78d77b412e1d0f72fca0b878f1e3</originalsourceid><addsrcrecordid>eNp1kktv1DAUhSMEoqWwZYksEN3N1I4Tx2GBVMqr0vAQKmvrxo9JBicebKfV_HgknOnQB2qVRWL7O-feHN8se07wnGDKj8Jq3vRxTipc1mX-INsnRcVmJWXlw2wf54zPKGX1XvYkhBXGpChw-TjbIxzzgtJyP_uzcMNyFrXvkRujdL0OyBkEarQxoIsutgjkGDWym37dusZCiJ1EVo-_dN8BApO0CMborFu6MYk9GgevLUStkHJDWjdu0KgH790Fih6GsLYwRIidG94gQKnoGnxanmsEA9hN6AJqNii2Gn3dUmDRl0v5-63hd--WHvpEK3Sih6kDk7ZPp6_hn-KddU5tkZ327Ko0-qGDBi_bp9kjAzboZ7v3Qfbz44ezk8-zxbdPpyfHi5lkhMSZbqjOVSOVZIoqhmlhwChTlrhqFFQFNZw2FVdV1RQk10RhU-VGAm54xQ3R9CB7e-m7HpteK5l69mDF2ncplo1w0InbJ0PXiqU7F3nJq6LIk8HhzsC736MOUfRdkNqmv9EpdVHhgjNeFwl89R-4cmMKxQaRsyInrOR0snt5L0UYK-s6r6-tlmC16AbjUmtyqiuOCWcFZZxWiZrfQaVHpfmQ6eZNl_ZvCQ5vCFoNNrbB2XG6tnCns_QuBK_NVV4Ei2n4RViJNPxiN_xJ8OJmytf4btoT8HoHQJBgTRoI2YUrLsc5JzWbKh9dciEdDUvtr-O5p_Rf8gskpw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216659929</pqid></control><display><type>article</type><title>Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Bishop, M R ; Logan, B R ; Gandham, S ; Bolwell, B J ; Cahn, J-Y ; Lazarus, H M ; Litzow, M R ; Marks, D I ; Wiernik, P H ; McCarthy, P L ; Russell, J A ; Miller, C B ; Sierra, J ; Milone, G ; Keating, A ; Loberiza, F R ; Giralt, S ; Horowitz, M M ; Weisdorf, D J</creator><creatorcontrib>Bishop, M R ; Logan, B R ; Gandham, S ; Bolwell, B J ; Cahn, J-Y ; Lazarus, H M ; Litzow, M R ; Marks, D I ; Wiernik, P H ; McCarthy, P L ; Russell, J A ; Miller, C B ; Sierra, J ; Milone, G ; Keating, A ; Loberiza, F R ; Giralt, S ; Horowitz, M M ; Weisdorf, D J</creatorcontrib><description>For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12–170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1705952</identifier><identifier>PMID: 18084335</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Acute lymphoblastic leukemia ; Acute lymphocytic leukemia ; Adolescent ; Adult ; Adults ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Autografts ; Biological and medical sciences ; Bone marrow ; Bone marrow transplantation ; Bone Marrow Transplantation - methods ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Care and treatment ; Cell Biology ; Comparative analysis ; Disease-Free Survival ; Female ; Graft Survival ; Hematologic and hematopoietic diseases ; Hematology ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic stem cells ; Humans ; Internal Medicine ; Kaplan-Meier Estimate ; Leukemia ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphatic leukemia ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local ; original-article ; Patient outcomes ; Patients ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Public Health ; Registries ; Retrospective Studies ; Stem cell transplantation ; Stem Cells ; Survival ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation, Autologous ; Transplantation, Homologous ; Transplants & implants ; Treatment Outcome</subject><ispartof>Bone marrow transplantation (Basingstoke), 2008-04, Vol.41 (7), p.635-642</ispartof><rights>Springer Nature Limited 2008</rights><rights>2008 INIST-CNRS</rights><rights>COPYRIGHT 2008 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2008</rights><rights>Nature Publishing Group 2008.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c611t-eb3e2dbcdc6d3d6034fafdf5507bda743f83b78d77b412e1d0f72fca0b878f1e3</citedby><cites>FETCH-LOGICAL-c611t-eb3e2dbcdc6d3d6034fafdf5507bda743f83b78d77b412e1d0f72fca0b878f1e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.bmt.1705952$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.bmt.1705952$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20281967$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18084335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bishop, M R</creatorcontrib><creatorcontrib>Logan, B R</creatorcontrib><creatorcontrib>Gandham, S</creatorcontrib><creatorcontrib>Bolwell, B J</creatorcontrib><creatorcontrib>Cahn, J-Y</creatorcontrib><creatorcontrib>Lazarus, H M</creatorcontrib><creatorcontrib>Litzow, M R</creatorcontrib><creatorcontrib>Marks, D I</creatorcontrib><creatorcontrib>Wiernik, P H</creatorcontrib><creatorcontrib>McCarthy, P L</creatorcontrib><creatorcontrib>Russell, J A</creatorcontrib><creatorcontrib>Miller, C B</creatorcontrib><creatorcontrib>Sierra, J</creatorcontrib><creatorcontrib>Milone, G</creatorcontrib><creatorcontrib>Keating, A</creatorcontrib><creatorcontrib>Loberiza, F R</creatorcontrib><creatorcontrib>Giralt, S</creatorcontrib><creatorcontrib>Horowitz, M M</creatorcontrib><creatorcontrib>Weisdorf, D J</creatorcontrib><title>Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12–170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.</description><subject>Acute lymphoblastic leukemia</subject><subject>Acute lymphocytic leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Autografts</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Comparative analysis</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Graft Survival</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemia</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphatic leukemia</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>original-article</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Public Health</subject><subject>Registries</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Transplantation, Homologous</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kktv1DAUhSMEoqWwZYksEN3N1I4Tx2GBVMqr0vAQKmvrxo9JBicebKfV_HgknOnQB2qVRWL7O-feHN8se07wnGDKj8Jq3vRxTipc1mX-INsnRcVmJWXlw2wf54zPKGX1XvYkhBXGpChw-TjbIxzzgtJyP_uzcMNyFrXvkRujdL0OyBkEarQxoIsutgjkGDWym37dusZCiJ1EVo-_dN8BApO0CMborFu6MYk9GgevLUStkHJDWjdu0KgH790Fih6GsLYwRIidG94gQKnoGnxanmsEA9hN6AJqNii2Gn3dUmDRl0v5-63hd--WHvpEK3Sih6kDk7ZPp6_hn-KddU5tkZ327Ko0-qGDBi_bp9kjAzboZ7v3Qfbz44ezk8-zxbdPpyfHi5lkhMSZbqjOVSOVZIoqhmlhwChTlrhqFFQFNZw2FVdV1RQk10RhU-VGAm54xQ3R9CB7e-m7HpteK5l69mDF2ncplo1w0InbJ0PXiqU7F3nJq6LIk8HhzsC736MOUfRdkNqmv9EpdVHhgjNeFwl89R-4cmMKxQaRsyInrOR0snt5L0UYK-s6r6-tlmC16AbjUmtyqiuOCWcFZZxWiZrfQaVHpfmQ6eZNl_ZvCQ5vCFoNNrbB2XG6tnCns_QuBK_NVV4Ei2n4RViJNPxiN_xJ8OJmytf4btoT8HoHQJBgTRoI2YUrLsc5JzWbKh9dciEdDUvtr-O5p_Rf8gskpw</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Bishop, M R</creator><creator>Logan, B R</creator><creator>Gandham, S</creator><creator>Bolwell, B J</creator><creator>Cahn, J-Y</creator><creator>Lazarus, H M</creator><creator>Litzow, M R</creator><creator>Marks, D I</creator><creator>Wiernik, P H</creator><creator>McCarthy, P L</creator><creator>Russell, J A</creator><creator>Miller, C B</creator><creator>Sierra, J</creator><creator>Milone, G</creator><creator>Keating, A</creator><creator>Loberiza, F R</creator><creator>Giralt, S</creator><creator>Horowitz, M M</creator><creator>Weisdorf, D J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080401</creationdate><title>Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research</title><author>Bishop, M R ; Logan, B R ; Gandham, S ; Bolwell, B J ; Cahn, J-Y ; Lazarus, H M ; Litzow, M R ; Marks, D I ; Wiernik, P H ; McCarthy, P L ; Russell, J A ; Miller, C B ; Sierra, J ; Milone, G ; Keating, A ; Loberiza, F R ; Giralt, S ; Horowitz, M M ; Weisdorf, D J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c611t-eb3e2dbcdc6d3d6034fafdf5507bda743f83b78d77b412e1d0f72fca0b878f1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Acute lymphocytic leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Autografts</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Comparative analysis</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Graft Survival</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemia</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphatic leukemia</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>original-article</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Public Health</topic><topic>Registries</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Transplantation, Homologous</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bishop, M R</creatorcontrib><creatorcontrib>Logan, B R</creatorcontrib><creatorcontrib>Gandham, S</creatorcontrib><creatorcontrib>Bolwell, B J</creatorcontrib><creatorcontrib>Cahn, J-Y</creatorcontrib><creatorcontrib>Lazarus, H M</creatorcontrib><creatorcontrib>Litzow, M R</creatorcontrib><creatorcontrib>Marks, D I</creatorcontrib><creatorcontrib>Wiernik, P H</creatorcontrib><creatorcontrib>McCarthy, P L</creatorcontrib><creatorcontrib>Russell, J A</creatorcontrib><creatorcontrib>Miller, C B</creatorcontrib><creatorcontrib>Sierra, J</creatorcontrib><creatorcontrib>Milone, G</creatorcontrib><creatorcontrib>Keating, A</creatorcontrib><creatorcontrib>Loberiza, F R</creatorcontrib><creatorcontrib>Giralt, S</creatorcontrib><creatorcontrib>Horowitz, M M</creatorcontrib><creatorcontrib>Weisdorf, D J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bishop, M R</au><au>Logan, B R</au><au>Gandham, S</au><au>Bolwell, B J</au><au>Cahn, J-Y</au><au>Lazarus, H M</au><au>Litzow, M R</au><au>Marks, D I</au><au>Wiernik, P H</au><au>McCarthy, P L</au><au>Russell, J A</au><au>Miller, C B</au><au>Sierra, J</au><au>Milone, G</au><au>Keating, A</au><au>Loberiza, F R</au><au>Giralt, S</au><au>Horowitz, M M</au><au>Weisdorf, D J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>41</volume><issue>7</issue><spage>635</spage><epage>642</epage><pages>635-642</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12–170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>18084335</pmid><doi>10.1038/sj.bmt.1705952</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2008-04, Vol.41 (7), p.635-642 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2587442 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; EZB-FREE-00999 freely available EZB journals |
| subjects | Acute lymphoblastic leukemia Acute lymphocytic leukemia Adolescent Adult Adults Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Autografts Biological and medical sciences Bone marrow Bone marrow transplantation Bone Marrow Transplantation - methods Bone marrow, stem cells transplantation. Graft versus host reaction Care and treatment Cell Biology Comparative analysis Disease-Free Survival Female Graft Survival Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Humans Internal Medicine Kaplan-Meier Estimate Leukemia Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphatic leukemia Male Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local original-article Patient outcomes Patients Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Public Health Registries Retrospective Studies Stem cell transplantation Stem Cells Survival Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Autologous Transplantation, Homologous Transplants & implants Treatment Outcome |
| title | Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T03%3A32%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcomes%20of%20adults%20with%20acute%20lymphoblastic%20leukemia%20after%20autologous%20or%20unrelated%20donor%20bone%20marrow%20transplantation:%20a%20comparative%20analysis%20by%20the%20National%20Marrow%20Donor%20Program%20and%20Center%20for%20International%20Blood%20and%20Marrow%20Transplant%20Research&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Bishop,%20M%20R&rft.date=2008-04-01&rft.volume=41&rft.issue=7&rft.spage=635&rft.epage=642&rft.pages=635-642&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1705952&rft_dat=%3Cgale_pubme%3EA186436837%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216659929&rft_id=info:pmid/18084335&rft_galeid=A186436837&rfr_iscdi=true |